Unprecedented Phase 1 CML efficacy data and potential best-in-disease profile of TERN-701 featured in ASH 2025 abstract Upcoming ASH oral ...

More about CML Microsystems. CML Microsystems Plc develops mixed-signal, RF, and microwave semiconductors for global comm ...

Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced ...

Various symptoms indicate chronic myelogenous leukemia (CML) has progressed from one phase to another. These include an increase in leukemia cells, a change in a person’s platelet count, and worsening ...

Chronic myelomonocytic leukemia (CMML) and chronic myeloid leukemia (CML) are two types of cancers that affect the blood and bone marrow. In both types, certain blood cells multiply out of control.

The company announced that data from the ongoing CARDINAL trial of TERN-701 in participants with previously treated chronic myeloid leukemia (CML) will be presented at the 67th American Society of ...

In October 2025, Terns Pharmaceuticals announced strongly positive Phase 1 data for TERN-701 in chronic myeloid leukemia, with a 75% major molecular response rate by 24 weeks and no dose-limiting ...

A lower number of CD26+ LSCs at diagnosis correlates with optimal molecular response in CML patients at 3, 12, and 24 months.

Investing.com -- Terns Pharmaceuticals (NASDAQ:TERN) stock surged 28% Tuesday, extending its two-day gain to 120% following positive clinical data for its TERN-701 treatment in relapsed/refractory ...

Chronic myeloid leukemia (CML) and chronic myelomonocytic leukemia (CMML) are two different types of cancer that affect the blood and bone marrow. In people with CML, the body creates abnormal white ...

Patient adherence to tyrosine kinase inhibitors (TKIs) ranges widely—from 19% to 100%—according to several studies. Most participants in the current study believed in the efficacy of their medication, ...

If this kind of company isn't your style, you like companies that generate revenue, and even earn profits, then you may well be interested in Coronation Fund Managers (JSE:CML). While this doesn't ...